Catalog name Description price
R-M1-cs8806 RVG29 modified liposomes loaded with paclitaxel The RVG29 modification on the liposomes provides a targeted approach to deliver paclitaxel specifically to neuronal cells, potentially for the treatment of neurological disorders or brain tumors. The RVG29 peptide interacts with nAChR on neuronal cells, promoting the endocytosis of the liposomes and subsequent release of the paclitaxel within the targeted cells.RVG29 modified liposomes loaded with paclitaxel offer the benefit of targeted drug delivery to neuronal cells, improving the efficacy and selectivity of paclitaxel treatment.RVG29 is a peptide derived from the rabies virus glycoprotein, which has a high affinity for the neuronal acetylcholine receptor (nAChR), specifically present on neuronal cells. By modifying liposomes with RVG29, they can be targeted specifically to neuronal cells, allowing for enhanced drug delivery to these cells. price>
R-M1-cs8807 Liposome loaded tectorigenin,surface modified peptide APWHLSSQYSRT The combination of liposome loaded tectorigenin and surface-modified peptide APWHLSSQYSRT refers to the preparation of liposomes that encapsulate tectorigenin, a natural compound, while the surface of the liposomes is modified with the peptide sequence APWHLSSQYSRT. Surface modification of liposomes with peptides, such as APWHLSSQYSRT, offers a way to enhance drug delivery and target specific cells or tissues. The sequence of the peptide may have been specifically designed to interact with a receptor or biomarker present on the surface of target cells. price>
R-M1-cs8810 SS31 peptide/simvastatin @ ROS responsive liposome By encapsulating SS31 peptide and simvastatin within ROS-responsive liposomes, it may be possible to achieve targeted delivery of both compounds to areas of high ROS levels, such as in certain disease states. The ROS-responsive liposomes are designed to release the encapsulated SS31 peptide and simvastatin in response to the presence of ROS, allowing for localized therapeutic effects and potentially enhanced efficacy. This combination could be explored in various biomedical applications, including the treatment of oxidative stress-related disorders or conditions where ROS plays a significant role, such as cardiovascular diseases, neurodegenerative disorders, or inflammation-associated conditions. price>
R-M1-8887 Fluvoxamine@LNP-TFR (sequence:THRPPMWSPVWP) 100nm The Fluvoxamine@Liposome nanoparticles-TFR (sequence: THRPPMWSPVWP) involves the targeted delivery of the therapeutic drug fluvoxamine using liposome nanoparticles functionalized with a peptide sequence that targets transferrin receptors. This type of drug delivery system has the potential to enhance the specificity and efficiency of drug delivery to particular cells or tissues in the body. price>
R-M2-9507 S2P(CRTLTVRKC)-PLGA-Maleimide-PEG2k nanoparticles containing Imatinib S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles/S2P(CRTLTVRKC)-PLGA-Maleimide-PEG2k nanoparticles containing Imatinib containing Imatinib for targeting drug delivery to atherosclerotic plaques.Stabilin-2 peptide with sequence of CRTLTVRKC is a specific ligand to stabilin-2,so it was synthesized for using as the targeting agent for atherosclerosis. price>
R-M2-9509 S2P Peptide-PLGA-Maleimide-PEG nanoparticles S2P peptide-PLGA-Maleimide-PEG nanoparticles/CRTLTVRKC-PLGA-Maleimide-PEG nanoparticles/S2P Peptide(CRTLTVRKC)-PLGA-Maleimide-PEG nanoparticles is a promising approach to targeted drug delivery. Targeting specific types of cancer cells using S2P peptides while delivering chemotherapeutics or RNA-based therapeutics.The system may be explored for delivering nucleic acids (DNA or RNA) for gene therapy applications, with the peptide aiding in cellular uptake.Utilizing this platform for delivering antigens or immune modulators to enhance immune response against tumors. price>
R-M2-9510 CRTLTVRKC-PLGA-PEG nanoparticles containing imatinib S2P Peptide-PLGA-PEG nanoparticles containing imatinib/S2P peptide (CRTLTVRKC) conjugated to PLGA-PEG nanoparticles is a sophisticated compound designed for improved delivery of imatinib. This approach aims to enhance the therapeutic efficacy of imatinib, a targeted treatment used primarily for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), while minimizing side effects through more effective targeting and controlled release.The nanoparticles can be engineered to also deliver other chemotherapy agents or to administer alongside imatinib to create combination therapies that enhance anti-tumor efficacy.The S2P peptide facilitates targeting specific cancer cells, potentially improving the therapeutic index of imatinib by concentrating the drug where it is most needed.The PLGA matrix allows for controlled release, promoting a prolonged therapeutic effect and minimizing the peaks and troughs associated with traditional dosing regimens.By targeting cancer cells specifically, the risk of side effects associated with systemic drug exposure can be reduced.The PEGylation process enhances the solubility and stability of the nanoparticles, improving bioavailability. price>
R-M1-8303 cRGD-liposomes @temozolomide and erastin cRGD-liposomes @temozolomide and erastin,Polypeptide cRGD modified liposomes coated with Temozolomide and erastin from kamulin. price>
R-M1-8386 Gold nanoparticles (15nm)-GSH Glutathione (GSH) is a water-soluble tripeptide that is contained in biological fluids (blood, cell fluid) and plays an important role in the redox process of human and animal organisms. Gold nanoparticles modified graphite electrodes have electrocatalytic activity for the oxidation of glutathione in alkaline media. price>
R-M1-8387 Gold nanoparticles (15nm)-Cys Gold nanoparticles (15nm)-Cys,Gold nanoparticles (AuNPs)-cysteine (C) It can be used for research in fields such as targeted delivery and biological imaging. It can be customized into Gold nanoparticles (AuNPs) wrapped in different sizes of cysteine (C). Gold nanoparticles (AuNPs) have their high stability, biocompatibility and functionality. price>